Symbols / BMEA
BMEA Chart
About
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 92.62M |
| Enterprise Value | 52.86M | Income | -95.71M | Sales | — |
| Book/sh | 0.26 | Cash/sh | 0.66 | Dividend Yield | — |
| Payout | 0.00% | Employees | 42 | IPO | — |
| P/E | — | Forward P/E | -1.25 | PEG | — |
| P/S | — | P/B | 5.00 | P/C | — |
| EV/EBITDA | -0.54 | EV/Sales | — | Quick Ratio | 3.00 |
| Current Ratio | 3.18 | Debt/Eq | 44.02 | LT Debt/Eq | — |
| EPS (ttm) | -2.25 | EPS next Y | -1.05 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-31 | ROA | -75.22% |
| ROE | -209.00% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 70.70M |
| Shs Float | 58.00M | Short Float | 17.16% | Short Ratio | 8.09 |
| Short Interest | — | 52W High | 3.50 | 52W Low | 0.87 |
| Beta | -0.18 | Avg Volume | 1.27M | Volume | 1.19M |
| Target Price | $7.00 | Recom | None | Prev Close | $1.28 |
| Price | $1.31 | Change | 2.34% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.00
Mean price target
2. Current target
$1.31
Latest analyst target
3. DCF / Fair value
$-14.16
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.31
Low
$4.00
High
$12.00
Mean
$7.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-13 | main | D. Boral Capital | Buy → Buy | $12 |
| 2025-11-10 | main | Citigroup | Buy → Buy | $6 |
| 2025-11-05 | main | D. Boral Capital | Buy → Buy | $12 |
| 2025-10-27 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-10-07 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-10-03 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-08-28 | init | Jefferies | — → Buy | $5 |
| 2025-08-11 | main | Citigroup | Buy → Buy | $7 |
| 2025-08-06 | main | Scotiabank | Sector Outperform → Sector Outperform | $10 |
| 2025-08-06 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-07-21 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-07-16 | main | Citigroup | Buy → Buy | $9 |
| 2025-06-24 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-06-18 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-06-13 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-05-15 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-05-06 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-05-06 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-04-02 | main | Barclays | Equal-Weight → Equal-Weight | $3 |
| 2025-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
- Biomea Fusion Updates Corporate Presentation on Metabolic Pipeline - TipRanks Wed, 25 Feb 2026 11
- Clinical-stage diabetes and obesity firm Biomea Fusion hits 3 investor events - Stock Titan hu, 19 Feb 2026 12
- $BMEA stock is down 10% today. Here's what we see in our data. - Quiver Quantitative hu, 15 Jan 2026 08
- BMEA Stock Price and Chart — NASDAQ:BMEA - TradingView Wed, 14 Jan 2026 08
- Rodman & Renshaw Initiates Biomea Fusion (BMEA) at Buy with $8 Price Target - Yahoo Finance Mon, 19 Jan 2026 08
- D. Boral Capital Maintains Biomea Fusion (BMEA) Buy Recommendation - Nasdaq Mon, 27 Oct 2025 07
- A Fresh Look at Biomea Fusion's (BMEA) Valuation Following Clinical Milestone and $25M Equity Raise - simplywall.st Fri, 10 Oct 2025 07
- Biomea Fusion stock soars after durable diabetes treatment results - Investing.com Fri, 05 Dec 2025 08
- Biomea Fusion (Nasdaq: BMEA) Grants 7,500-Share Inducement Option to New Employee - Stock Titan Mon, 01 Dec 2025 08
- Biomea Fusion, Inc.'s (NASDAQ:BMEA) largest shareholders are retail investors with 55% ownership, institutions own 38% - Yahoo Finance Sat, 24 Jan 2026 08
- Interim CEO & Director of Biomea Fusion Michael J. Hitchcock Buys 667% More Shares - simplywall.st hu, 11 Dec 2025 08
- $25M Offering: Biomea Fusion Prices 11.2M Shares & Warrants at $2.05 — Closing Oct 8, 2025 - Stock Titan ue, 07 Oct 2025 07
- Insider Purchase: Interim CEO of $BMEA Buys 100,000 Shares | BMEA Stock News - Quiver Quantitative hu, 04 Dec 2025 08
- Why Biomea Fusion (BMEA) Is Up After Positive Diabetes Data and $25M Equity Raise – And What’s Next - Yahoo Finance Wed, 08 Oct 2025 07
- Biomea Fusion (Nasdaq: BMEA) features KOL talk on menin, icovamenib at WCIRDC 2025 - Stock Titan ue, 09 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 150600 | — | — | Stock Gift at price 0.00 per share. | ERDTMANN RAINER M | President | — | 2025-12-31 00:00:00 | D |
| 1 | 30000 | 42999 | — | Purchase at price 1.43 per share. | ERDTMANN RAINER M | President | — | 2025-12-11 00:00:00 | D |
| 2 | 100000 | 99180 | — | Purchase at price 0.99 per share. | HITCHCOCK MICHAEL J.M. | Chief Executive Officer | — | 2025-12-02 00:00:00 | D |
| 3 | 50000 | 54552 | — | Purchase at price 1.05 - 1.10 per share. | ERDTMANN RAINER M | President | — | 2025-12-01 00:00:00 | D |
| 4 | 70000 | — | — | Stock Gift at price 0.00 per share. | ERDTMANN RAINER M | President | — | 2025-01-31 00:00:00 | D |
| 5 | 495 | 3046 | — | Stock Award(Grant) at price 6.15 per share. | VALLE FRANCO | Chief Financial Officer | — | 2024-11-29 00:00:00 | D |
| 6 | 10000 | 100600 | — | Purchase at price 10.06 per share. | HITCHCOCK MICHAEL J.M. | Director | — | 2024-09-30 00:00:00 | D |
| 7 | 12509 | 55361 | — | Purchase at price 4.43 per share. | VALLE FRANCO | Chief Financial Officer | — | 2024-06-11 00:00:00 | D |
| 8 | 4448 | 46793 | — | Stock Award(Grant) at price 10.52 per share. | VALLE FRANCO | Chief Financial Officer | — | 2024-05-31 00:00:00 | D |
| 9 | 349 | 3121 | — | Stock Award(Grant) at price 8.94 per share. | FRIAS JUAN PABLO | Officer | — | 2024-05-31 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -142.32M | -124.62M | -82.94M | -41.42M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -138.43M | -117.25M | -81.83M | -41.57M |
| ReconciledDepreciation | 1.75M | 1.51M | 691.00K | 249.00K |
| EBITDA | -142.32M | -124.62M | -82.94M | -41.42M |
| EBIT | -144.07M | -126.14M | -83.63M | -41.67M |
| NetInterestIncome | 5.64M | 8.88M | 1.81M | 100.00K |
| InterestIncome | 5.64M | 8.88M | 1.81M | 100.00K |
| NormalizedIncome | -138.43M | -117.25M | -81.83M | -41.57M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -138.43M | -117.25M | -81.83M | -41.57M |
| TotalExpenses | 144.07M | 126.14M | 83.63M | 41.67M |
| TotalOperatingIncomeAsReported | -144.07M | -126.14M | -83.63M | -41.67M |
| DilutedAverageShares | 36.11M | 34.11M | 29.27M | 23.86M |
| BasicAverageShares | 36.11M | 34.11M | 29.27M | 23.86M |
| DilutedEPS | -3.83 | -3.44 | -2.80 | -1.74 |
| BasicEPS | -3.83 | -3.44 | -2.80 | -1.74 |
| DilutedNIAvailtoComStockholders | -138.43M | -117.25M | -81.83M | -41.57M |
| NetIncomeCommonStockholders | -138.43M | -117.25M | -81.83M | -41.57M |
| NetIncome | -138.43M | -117.25M | -81.83M | -41.57M |
| NetIncomeIncludingNoncontrollingInterests | -138.43M | -117.25M | -81.83M | -41.57M |
| NetIncomeContinuousOperations | -138.43M | -117.25M | -81.83M | -41.57M |
| PretaxIncome | -138.43M | -117.25M | -81.83M | -41.57M |
| NetNonOperatingInterestIncomeExpense | 5.64M | 8.88M | 1.81M | 100.00K |
| TotalOtherFinanceCost | -100.00K | |||
| InterestIncomeNonOperating | 5.64M | 8.88M | 1.81M | 100.00K |
| OperatingIncome | -144.07M | -126.14M | -83.63M | -41.67M |
| OperatingExpense | 144.07M | 126.14M | 83.63M | 41.67M |
| ResearchAndDevelopment | 118.08M | 102.55M | 62.71M | 28.00M |
| SellingGeneralAndAdministration | 25.98M | 23.59M | 20.92M | 13.67M |
| GeneralAndAdministrativeExpense | 25.98M | 23.59M | 20.92M | 13.67M |
| OtherGandA | 25.98M | 23.59M | 20.92M | 13.67M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 36.31M | 35.87M | 29.56M | 29.12M |
| ShareIssued | 36.31M | 35.87M | 29.56M | 29.12M |
| TotalDebt | 8.77M | 10.30M | 2.29M | 2.85M |
| TangibleBookValue | 51.57M | 169.24M | 108.54M | 178.78M |
| InvestedCapital | 51.57M | 169.24M | 108.54M | 178.78M |
| WorkingCapital | 46.66M | 156.32M | 98.72M | 171.92M |
| NetTangibleAssets | 51.57M | 169.24M | 108.54M | 178.78M |
| CapitalLeaseObligations | 8.77M | 10.30M | 2.29M | 2.85M |
| CommonStockEquity | 51.57M | 169.24M | 108.54M | 178.78M |
| TotalCapitalization | 51.57M | 169.24M | 108.54M | 178.78M |
| TotalEquityGrossMinorityInterest | 51.57M | 169.24M | 108.54M | 178.78M |
| StockholdersEquity | 51.57M | 169.24M | 108.54M | 178.78M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -1.00K | -10.00K | |
| OtherEquityAdjustments | -1.00K | -10.00K | ||
| RetainedEarnings | -387.25M | -248.82M | -131.57M | -49.74M |
| AdditionalPaidInCapital | 438.82M | 418.06M | 240.11M | 228.53M |
| CapitalStock | 4.00K | 4.00K | 3.00K | 3.00K |
| CommonStock | 4.00K | 4.00K | 3.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 28.36M | 30.69M | 20.77M | 6.92M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 6.69M | 7.83M | 1.67M | 2.29M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 6.69M | 7.83M | 1.67M | 2.29M |
| LongTermCapitalLeaseObligation | 6.69M | 7.83M | 1.67M | 2.29M |
| CurrentLiabilities | 21.67M | 22.86M | 19.10M | 4.64M |
| OtherCurrentLiabilities | 203.00K | 192.00K | 636.00K | 480.00K |
| CurrentDebtAndCapitalLeaseObligation | 2.08M | 2.47M | 618.00K | 565.00K |
| CurrentCapitalLeaseObligation | 2.08M | 2.47M | 618.00K | 565.00K |
| PayablesAndAccruedExpenses | 19.39M | 20.20M | 17.85M | 3.59M |
| CurrentAccruedExpenses | 6.46M | 13.35M | 11.02M | 2.26M |
| Payables | 12.93M | 6.85M | 6.83M | 1.33M |
| AccountsPayable | 12.93M | 6.85M | 6.83M | 1.33M |
| TotalAssets | 79.94M | 199.93M | 129.31M | 185.71M |
| TotalNonCurrentAssets | 11.61M | 20.75M | 11.49M | 9.14M |
| OtherNonCurrentAssets | 988.00K | 5.87M | 3.50M | 1.58M |
| InvestmentsAndAdvances | 0.00 | 0.00 | 1.88M | |
| NetPPE | 10.62M | 14.87M | 7.99M | 5.69M |
| AccumulatedDepreciation | -4.18M | -2.43M | -916.00K | -257.00K |
| GrossPPE | 14.80M | 17.30M | 8.91M | 5.94M |
| Leases | 3.44M | 3.19M | 801.00K | 828.00K |
| ConstructionInProgress | 0.00 | 4.00K | 3.17M | 81.00K |
| OtherProperties | 10.78M | 13.57M | 4.48M | 4.60M |
| MachineryFurnitureEquipment | 578.00K | 539.00K | 455.00K | 439.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 68.33M | 179.18M | 117.82M | 176.56M |
| OtherCurrentAssets | 10.05M | 2.31M | 4.77M | 3.04M |
| PrepaidAssets | 3.04M | |||
| CashCashEquivalentsAndShortTermInvestments | 58.28M | 176.87M | 113.05M | 173.52M |
| OtherShortTermInvestments | 0.00 | 1.15M | 27.78M | |
| CashAndCashEquivalents | 58.28M | 176.87M | 111.90M | 145.74M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -120.26M | -99.96M | -63.45M | -38.61M |
| IssuanceOfCapitalStock | 0.00 | 161.80M | 0.00 | 152.75M |
| CapitalExpenditure | -362.00K | -3.37M | -1.03M | -3.17M |
| EndCashPosition | 58.65M | 177.24M | 112.25M | 146.09M |
| BeginningCashPosition | 177.24M | 112.25M | 146.09M | 61.70M |
| ChangesInCash | -118.59M | 64.99M | -33.84M | 84.39M |
| FinancingCashFlow | 1.67M | 163.80M | 1.24M | 153.19M |
| CashFlowFromContinuingFinancingActivities | 1.67M | 163.80M | 1.24M | 153.19M |
| ProceedsFromStockOptionExercised | 1.67M | 2.00M | 1.24M | 468.00K |
| NetPreferredStockIssuance | 0.00 | 0.00 | ||
| PreferredStockIssuance | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 0.00 | 161.80M | 0.00 | 152.75M |
| CommonStockIssuance | 0.00 | 161.80M | 0.00 | 152.75M |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | -36.00K | |
| NetLongTermDebtIssuance | 0.00 | 0.00 | -36.00K | |
| InvestingCashFlow | -362.00K | -2.22M | 27.34M | -33.35M |
| CashFlowFromContinuingInvestingActivities | -362.00K | -2.22M | 27.34M | -33.35M |
| NetInvestmentPurchaseAndSale | 0.00 | 1.15M | 28.37M | -30.18M |
| SaleOfInvestment | 0.00 | 1.15M | 28.37M | 8.31M |
| PurchaseOfInvestment | 0.00 | 0.00 | -38.49M | |
| NetPPEPurchaseAndSale | -362.00K | -3.37M | -1.03M | -3.17M |
| PurchaseOfPPE | -362.00K | -3.37M | -1.03M | -3.17M |
| OperatingCashFlow | -119.89M | -96.59M | -62.42M | -35.44M |
| CashFlowFromContinuingOperatingActivities | -119.89M | -96.59M | -62.42M | -35.44M |
| ChangeInWorkingCapital | -5.15M | 2.33M | 7.67M | -1.57M |
| ChangeInOtherCurrentLiabilities | -1.50M | -2.24M | -565.00K | -589.00K |
| ChangeInOtherCurrentAssets | 4.88M | -2.36M | -1.92M | -1.22M |
| ChangeInPayablesAndAccruedExpense | -793.00K | 4.45M | 11.87M | 2.75M |
| ChangeInAccruedExpense | -6.88M | 1.89M | 8.91M | 2.11M |
| ChangeInPayable | 6.09M | 2.56M | 2.96M | 640.00K |
| ChangeInAccountPayable | 6.09M | 2.56M | 2.96M | 640.00K |
| ChangeInPrepaidAssets | -7.74M | 2.48M | -1.73M | -2.52M |
| OtherNonCashItems | 2.84M | 2.69M | 571.00K | 704.00K |
| StockBasedCompensation | 19.09M | 14.13M | 10.34M | 6.23M |
| AmortizationOfSecurities | 0.00 | 1.00K | 144.00K | 516.00K |
| DepreciationAmortizationDepletion | 1.75M | 1.51M | 691.00K | 249.00K |
| DepreciationAndAmortization | 1.75M | 1.51M | 691.00K | 249.00K |
| Depreciation | 1.75M | 1.51M | 691.00K | 249.00K |
| NetIncomeFromContinuingOperations | -138.43M | -117.25M | -81.83M | -41.57M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BMEA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|